Jul 14, 2026·Score 75·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$112.41
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$105.00($100.00–$110.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$120.80
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - Kimberly-Clark Corporation (KMB) 20260714 Stock Analysis
📅 Kimberly-Clark Key Upcoming Events
August 04, 2026Q2 2026 Earnings Release and Conference Call
Description: Management is scheduled to report second-quarter performance, providing critical updates on organic volume growth, Pricing Net of Commodity (PNOC) execution, and the specific financial impact of recent distribution center incidents in California. Investors will be heavily focused on margin sustainability amidst fluctuating pulp and resin costs.
H2 2026Anticipated Closure of the $48.7 Billion Kenvue Acquisition
Description: Following overwhelming shareholder approval in January 2026, the transformational cash-and-stock merger is expected to close. This event will formally integrate Kenvue’s massive consumer health portfolio (including Tylenol, Neutrogena, and Listerine) into Kimberly-Clark, fundamentally shifting the company’s Total Addressable Market (TAM) and margin profile.
H2 2026Closure of International Family Care & Professional (IFP) Joint Venture
Description: The $1.7 billion transaction with Suzano, wherein Kimberly-Clark divests a 51% stake of its IFP business, is expected to close. This strategic divestiture optimizes the company’s geographic footprint and generates essential cash liquidity to partially fund the cash consideration of the monumental Kenvue acquisition.
🏢 Step 1: Kimberly-Clark Company Overview & Business Model
Q1-A1. What is Kimberly-Clark?
Company Name (Ticker): Kimberly-Clark Corporation (KMB)
Sector: Consumer Staples
Exchange: NASDAQ
Founded: March 26, 1872
Listing Date: May 08, 1929
Fiscal Year End: December
Headquarters: United States, Irving
CEO: Michael D. Hsu
Market Cap: $37.31B
Shares Outstanding: 331.94M
Current Stock Price: $112.41
Annual Dividend Yield: 4.55% (historical basis)
As-of: July 14, 2026 (ET)
Q1-A2. How Does Kimberly-Clark Make Money?
Business Model: Kimberly-Clark operates as a dominant global manufacturer of personal care, consumer tissue, and professional hygiene products, producing fast-moving consumer goods (FMCG) that serve billions of people worldwide. The company generates robust, recurring revenue streams by producing essential, daily-use items that enjoy deep brand loyalty and high household penetration.
Core Mechanisms: The firm operates a high-volume, continuous-replenishment model. By focusing intensely on consumer-inspired innovation, science-backed product development, and a tiered “Good, Better, Best” premiumization strategy within vital categories like Baby & Child Care and Adult Care, it successfully commands brand loyalty that supports vital pricing power over cheaper private-label alternatives. The impending integration of Kenvue will profoundly expand this model into the higher-margin, science-backed consumer health and wellness ecosystem.
Q1-A3. Kimberly-Clark’s Revenue Segments & Core Income Sources
North America (NA) (approx. 63% of core revenue): This segment serves as the historical foundation and cash cow of the business, generating massive operating cash flows through universally recognized, dominant brands such as Huggies, Kleenex, Cottonelle, and Depend. It represents the highest margin profile within the legacy business and acts as the primary beneficiary of the company’s recent pricing optimization efforts and targeted premiumization.
International Personal Care (IPC) (approx. 37% of core revenue): Focused on both emerging and developed markets outside North America, this segment has historically acted as the primary volume growth engine. It expands market share in densely populated regions like China, Indonesia, and Latin America by targeting a rising middle class with premium feminine and baby care products.
Upcoming Segment Reconfiguration (Post-Kenvue): Upon the final closure of the Kenvue acquisition, the company will undergo a massive transition to four distinct geographic segments: North America (estimated ≈$18.0B), EMEA (≈$5.0B), Asia Pacific Focus Markets (≈$4.3B), and Enterprise Markets (≈$4.3B). This reconfiguration will vastly expand its revenue base to an estimated $32 billion annually, creating a globally diversified health and hygiene behemoth.
Q1-A4. Who Are Kimberly-Clark’s Competitors?
Direct Competitors: Procter & Gamble (P&G) remains the fiercest and largest global rival, engaging in intense, ongoing battles for market share, particularly in the highly lucrative diaper category (Pampers vs. Huggies) and feminine care. Other significant direct competitors include Edgewell Personal Care, Unicharm, Essity, and Church & Dwight, all vying for shelf space and consumer loyalty in specialized personal care niches.
Substitutes and Private Label: Store-brand (private label) tissue and personal care products pose a persistent, structural threat to market share, especially during periods of macroeconomic tightening when heavily squeezed consumers attempt to trade down. However, Kimberly-Clark’s strategic emphasis on its “Good, Better, Best” tiering strategy and continuous product innovation actively defends against aggressive private-label encroachment by offering distinct value propositions at various price points.
Industry Position: Kimberly-Clark holds the #1 or #2 market share position in approximately 70 countries worldwide. While P&G may be larger in overall corporate scale, Kimberly-Clark heavily dominates specific high-margin niches, particularly in the rapidly growing adult incontinence market (Depend, Poise) and specific regional baby care markets where localized brand equity remains unmatched.
Q1-A5. Kimberly-Clark Key Events: Past 12 Months
June 05, 2025Announced $1.7 Billion Joint Venture with Suzano
Description: Kimberly-Clark strategically agreed to sell a 51% stake in its International Family Care and Professional (IFP) business to Suzano, streamlining its global portfolio toward higher-margin personal care segments and raising necessary capital.
July 01, 2025Completed Divestiture of Personal Protective Equipment (PPE) Business
Description: The company successfully closed the sale of its PPE business, which included the Kimtech and KleenGuard brands, for total consideration of $635 million, recognizing a substantial pre-tax gain and further focusing internal resources on core consumer hygiene products.
November 03, 2025Announced $48.7 Billion Mega-Acquisition of Kenvue
Description: In a historic pivot, the company signed a definitive agreement to acquire consumer health leader Kenvue in a cash-and-stock transaction, aiming to create a global health and wellness giant with projected combined revenues of $32 billion and $7 billion in adjusted EBITDA.
January 29, 2026Shareholders Overwhelmingly Approve Kenvue Merger
Description: Approximately 96% of Kimberly-Clark shares voted in favor of issuing the new stock required to facilitate the transaction, clearing a major regulatory and governance hurdle toward the expected H2 2026 closure.
April 28, 2026Reported Strong Q1 2026 Earnings Beat
Description: The company reported an adjusted EPS of $1.97, soundly beating analyst estimates of $1.93, alongside organic sales growth of 2.5%, driven by a 3.0% volume-plus-mix expansion and aggressive productivity savings under the 2024 Transformation Initiative.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: Kimberly-Clark is currently undergoing the most profound structural transformation in its 150-year history. While traditionally viewed as a highly stable, slow-growing consumer staples firm reliant on paper products, the impending $48.7 billion acquisition of Kenvue will radically shift its corporate identity toward consumer health. This move vastly expands its total addressable market and margin ceiling while simultaneously introducing monumental integration complexities and near-term capital structure adjustments.
Top 3 Red Flags:
1 The sheer scale and complexity of the Kenvue acquisition pose massive operational integration risks and involve highly significant shareholder dilution due to the required issuance of approximately 280 million new shares.
2 Exposure to inherently volatile commodity input costs (particularly pulp and petroleum-based resins) continues to necessitate aggressive pricing strategies, which may eventually encounter severe consumer pushback if inflation accelerates.
3 Exceptionally high levels of short interest (approximately 13%) suggest heavy merger-arbitrage positioning that currently acts as a mechanical ceiling, capping any near-term stock price appreciation.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 Progress and realization rates on the 2024 Transformation Initiative, specifically targeting $3.0 billion in gross productivity savings.
2 Volume-plus-mix growth trends within the high-margin North America segment.
3 Operating margin expansion driven by strict Pricing Net of Commodity (PNOC) execution discipline.
5 Dividend payout sustainability and growth capacity amidst dramatically increased capital expenditures and M&A cash requirements.
Top 3 Unconfirmed and Estimated:
1 The exact realization timeline and operational friction of achieving the $1.9 billion in anticipated cost synergies from the Kenvue integration.
2 Final regulatory approval dates and potential required regional divestitures for both the Kenvue acquisition and the Suzano IFP joint venture across all international jurisdictions.
3 The finalized, precise financial impact of the California distribution center fire, currently estimated at a $20 million sales impact, expected to hit Q2 2026 results.
🏰 Step 2: Kimberly-Clark’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Kimberly-Clark Have a Durable Economic Moat?
Entry barriers: Kimberly-Clark benefits from a highly robust Intangible Asset moat underpinned by globally recognized, century-old brands such as Huggies, Kleenex, and Kotex. Furthermore, the massive, deeply entrenched scale of its global manufacturing and logistics distribution networks creates profound Cost Advantages. It is virtually impossible for new, smaller entrants to match its manufacturing unit economics, secure equivalent shelf-space dominance in major retailers like Walmart or Costco, or fund the requisite multi-million dollar marketing campaigns necessary to shift ingrained consumer habits.
Pricing Power: The company demonstrates resilient, structural pricing power, evidenced by its ability to execute its Pricing Net of Commodity (PNOC) strategy. Despite navigating recent periods of severe, unprecedented inflationary pressures on underlying pulp and energy costs, Kimberly-Clark successfully passed these increased costs directly to end consumers. It achieved this while maintaining gross margins in the 36% to 37% range, entirely avoiding catastrophic volume deterioration, proving that consumers view its products as essential staples rather than discretionary purchases.
Profitability Defense: The company maintains a highly durable Return on Invested Capital (ROIC) averaging historically over 20%, vastly exceeding its Weighted Average Cost of Capital (WACC) of roughly 6.5% to 7.5%. This wide, sustained spread confirms that its economic moat actively and continuously protects excess economic returns from being competed away by industry rivals.
Q2-A2. Is Kimberly-Clark’s Growth Sustainable?
Industry Structure and Growth Outlook: The traditional consumer tissue and basic hygiene market is structurally mature, historically growing at a highly modest 2% to 3% annually in developed economies. However, the aggressive strategic pivot toward consumer health via the Kenvue acquisition dramatically shifts Kimberly-Clark into a structurally faster-growing total addressable market (TAM). This new health and wellness sector is characterized by higher operating margins and powerful secular tailwinds, including proactive personal health management, the premiumization of self-care, and the expanding needs of active aging populations driving sustained demand for both OTC medications and specialized incontinence products.
Growth Sustainability: Organic growth within the legacy core business is highly reliant on continuous product innovation (such as premiumizing diaper technologies and feminine care materials) rather than relying purely on organic population expansion.
Downside Scenario 1: A severe, prolonged global recession forces consumers to broadly abandon brand loyalty and trade down permanently to private-label hygiene products, shattering the company’s carefully constructed volume-plus-mix momentum and deeply compressing gross margins.
Downside Scenario 2: The $48.7 billion Kenvue integration becomes mired in cultural and operational friction. Management distraction leads to a failure to realize the $2.1 billion in projected net synergies, destroying immense shareholder value and leaving the company burdened by unmanageable acquisition debt.
Downside Scenario 3: Unprecedented, sustained spikes in global pulp and petroleum-based resin prices compress raw material margins significantly faster than the company can responsibly raise retail prices, resulting in a severe, unavoidable margin squeeze that forces a cut in innovation reinvestment.
Q2-A3. How Does Kimberly-Clark Allocate Capital & Return Cash?
Capital Allocation Priorities: Executive management has historically prioritized a highly balanced, predictable approach to capital allocation: funding essential supply-chain capital expenditures (averaging $700M to $800M annually), maintaining a pristine, unbroken 53-year streak of dividend increases, and executing strategic, bolt-on M&A. The monumental Kenvue acquisition marks a radical, structural departure from this historically conservative capital allocation framework, utilizing billions in upfront cash, assuming new debt, and issuing massive equity to fundamentally alter the company’s long-term trajectory and margin ceiling.
Shareholder Returns: Kimberly-Clark is a definitive, undisputed “Dividend King.” The current annual dividend payout of $5.12 per share offers a highly generous yield of approximately 4.55%, easily doubling the average yield of the broader S&P 500 market. While share repurchases have historically been a massive pillar of its total shareholder returns (steadily reducing the share count over decades), the impending issuance of ≈280 million shares to fund the Kenvue transaction violently shifts the near-term capital focus away from buybacks. For the next three to five years, capital allocation must be entirely subordinated to M&A integration execution, realizing targeted synergies, and aggressive debt deleveraging.
Economic Moat (8/10): The company possesses exceptional brand equity and unmatched global cost advantages, though this is slightly offset by the inherent, structural commoditization risks of basic tissue and paper products.
Growth Sustainability (7/8): The bold Kenvue deal radically improves the long-term structural growth profile, moving the company out of stagnant demographics and into the higher-growth, higher-margin consumer health ecosystem.
Capital Allocation (6/7): An elite, virtually unmatched dividend track record and bold strategic M&A vision are commendable, though the heavy equity dilution required for the Kenvue transaction introduces significant medium-term capital structure friction and leverage risks.
Step 2 Summary: Kimberly-Clark possesses a formidable, historically entrenched brand-driven economic moat. Management’s bold capital allocation pivot via the Kenvue mega-merger successfully and permanently transitions the company out of a purely mature, slow-growth market into a highly profitable consumer health ecosystem, securing its growth runway for the next decade.
💰 Step 3: Is Kimberly-Clark Profitable? Financial Health Analysis
Growth and Revenue Indicators: Following years of relatively stagnant ≈1% to 2% revenue growth, the company generated $16.45 billion in 2025. While the reported top-line revenue saw a slight 2.1% contraction, this was largely an artificial artifact caused by strategic divestitures (such as the PPE business) and intentional exits from low-margin businesses (like the private label diaper segment) rather than declining consumer demand. The true health of the business is reflected in its core organic sales, which grew by 2.5%, driven powerfully by a 3.0% volume-plus-mix improvement that highlights consumers’ willingness to pay for premium innovation.
Profitability Margin and Leverage: The company is masterfully executing on operating leverage. Driven by the 2024 Transformation Initiative, gross margins expanded robustly back to the ≈37% range, and adjusted operating margins reached an impressive 18.1% in recent quarters. This proves definitively that the ongoing $3 billion productivity program is successfully offsetting raw material inflation and allowing sales growth to drop directly to the bottom line.
Q3-A2. How Profitable Is Kimberly-Clark? (Margins & ROIC)
ROIC and Value Creation: Kimberly-Clark consistently generates an absolutely outstanding Return on Invested Capital (ROIC). Recent TTM ROIC stands at 25.62% (and historically averages well above 20%). This aggressively outpaces its estimated Weighted Average Cost of Capital (WACC) of approximately 6.5% to 7.5%, indicating massive, compounding economic value added for every single dollar retained and reinvested in the core business.
Margin Comparison: Its 16% to 18% operating margins lag slightly behind the absolute top tier of the broader consumer staples sector (such as P&G’s >20% margins), but they are exceptionally strong for a company heavily weighted in raw-material-intensive paper, pulp, and tissue products, showcasing world-class supply chain efficiency.
Q3-A3. What Drives Kimberly-Clark’s Returns? (ROIC Breakdown)
Industry-specific Efficiency: As a classic Fast-Moving Consumer Goods (FMCG) manufacturer, Kimberly-Clark’s immense ROIC is fundamentally driven by high asset turnover paired with gross margin expansion through relentless brand premiumization and packaging innovation.
Asset Turnover and Plant Utilization: The company maintains an asset turnover ratio approaching 1.0x. By systematically streamlining its global supply chain under the massive 2024 Transformation Initiative—specifically through Value Stream Simplification and Scalable Automation—it is aggressively reducing its physical manufacturing footprint. This boosts output volume per facility, driving structurally higher returns on fixed physical assets and minimizing idle downtime.
Q3-A4. Are Kimberly-Clark’s Earnings High Quality?
Earnings to Cash Discrepancy: The fundamental quality of Kimberly-Clark’s earnings is pristine. Operating cash flow heavily tracks, and often exceeds, reported net income. In 2025, the company generated $2.77 billion in Free Cash Flow (FCF) against $2.02 billion in net income, showcasing supreme cash conversion capabilities.
Cash Conversion Trend: The FCF/Net Income ratio is consistently well above 1.0x (averaging 120%+ over the last several years), confirming beyond doubt that the book profits reported on the income statement are fully backed by hard, liquid cash generation without relying on aggressive working capital distortions or accounting gimmicks.
Q3-A5. Is Kimberly-Clark’s Balance Sheet Healthy? (Debt & Leverage)
Debt Structure and Leverage: On paper, the balance sheet carries high nominal leverage. Total debt sits at $7.11 billion against a highly diminished book equity of $1.91 billion. This results in a technically extreme Debt/Equity ratio of 371%. However, this is largely an accounting artifact resulting from decades of aggressive treasury stock accumulation via share buybacks, which technically erodes book equity but signals immense historical cash generation.
Solvency and Interest Coverage: Despite the optically distorted debt-to-equity ratio, solvency is absolutely not a concern. The Interest Coverage Ratio sits at a robust 11.9x, proving that the operating income generated from core businesses effortlessly covers all debt servicing obligations with massive room to spare.
Kenvue Deal Impact: The upcoming Kenvue acquisition will significantly alter this debt profile, adding billions in new acquisition debt alongside the massive equity issuance, requiring meticulous, disciplined deleveraging execution by management over the next 24 to 36 months to protect the company’s credit rating.
Profitability·Capital Efficiency (8/10): Exceptional ROIC and impressively recovering gross margins, though the company is still completing its recovery from previous inflationary margin compression shocks.
Cash Flow·Profit Quality (7/8): Brilliant, top-tier cash conversion metrics, consistently turning over 100% of net income into highly liquid free cash flow.
Financial Soundness·Debt Management (5/7): Exceptionally strong interest coverage, but massive nominal leverage and the impending assumption of billions in new acquisition debt introduce material balance sheet friction that requires monitoring.
Step 3 Summary: Kimberly-Clark is a highly profitable, cash-gushing enterprise. While book equity looks optically weak due to historical buybacks, the actual operational cash flow effortlessly services its debt obligations. However, the massive Kenvue merger will test the absolute limits of this balance sheet elasticity, requiring flawless cash management post-close.
Q4-A1. Does Kimberly-Clark Have Accounting Red Flags?
Revenue recognition: not found
Evidence: Revenue is recognized standardly and conservatively upon the transfer of control for FMCG goods. There are zero SEC investigations, restatements, or whistleblower complaints regarding channel stuffing or premature revenue recognition present in recent filings.
Cost capitalization: not found
Evidence: Capital expenditures track closely with depreciation schedules. The 2024 Transformation Initiative charges ($808 million cumulative pre-tax through 2025) are highly transparent and meticulously delineated between cash severance payouts and non-cash asset write-offs, preventing any masking of operational expenses.
Sharp increase in accounts receivable and inventory: not found
Evidence: Inventory turnover remains highly stable at around 6.1x (TTM). Days sales in receivables sits at a healthy 43 days, entirely standard for the industry’s retail distribution networks, indicating customers are paying on time without extended credit terms.
Evidence: The company heavily utilizes non-GAAP adjustments to strip out the $808 million in charges related to the Transformation Initiative and the significant separation costs tied to the IFP/Suzano divestiture. While the magnitude of these adjustments is significant, they are clearly documented in footnotes and aligned with massive physical footprint restructuring, rather than being used as a persistent tool for operational masking.
Q4-A2. Is Kimberly-Clark Overspending? (Capex & Capital Cycle)
Capital Cycle Assessment: Capital expenditures remain highly disciplined and predictable. The company spent approximately $741 million in a recent 9-month tracking period, highly consistent with its historical run-rate of allocating roughly 4.5% of revenue toward capital improvements. There is zero evidence of reckless capacity expansion or empire-building; in fact, the Transformation Initiative actively works to reduce redundant manufacturing capacity and heavily automate existing lines to improve unit economics.
Q4-A3. How Sound Is Kimberly-Clark’s Cash Flow?
Quality of Profits: The operating cash flow overwhelmingly eclipses reported net income. The company generated $1.8 billion in Operating Cash Flow year-to-date against lower reported net income, largely due to high non-cash depreciation and the aforementioned restructuring charges. There are zero signs of fictitious earnings or aggressive accrual accounting.
Financing Dependency: The firm is entirely self-sufficient. It funds its aggressive, $1.5+ billion annual dividend commitment entirely through internally generated free cash flow, strictly avoiding the dangerous trap of borrowing externally simply to fund shareholder payouts.
Q4-A4. Is Kimberly-Clark Diluting Shareholders?
⏪ Confirmed (Past) Dilution: Historically, Kimberly-Clark was a massive net buyer of its own stock in the open market, consistently reducing outstanding shares to the current ≈331.9 million level and acting as a major pillar of EPS growth. Stock-based compensation (SBC) has been kept minimal (e.g., $23 million in a recent quarter) and fully offset by these aggressive buybacks.
⏩ Potential (Future) Dilution & Overhang:Massive Dilution Imminent. The definitive agreement to acquire Kenvue contractually requires Kimberly-Clark to issue approximately 280 million new shares of common stock. This staggering issuance will nearly double the outstanding share count overnight, heavily diluting existing shareholders’ ownership to approximately 54% of the combined pro-forma entity. This creates a massive structural overhang on the stock until the deal formally closes and the promised $2.1 billion in run-rate synergies are definitively proven.
Number of shares: 331.94M basic outstanding verified against platform data ➡ (Pass)
Unit: USD Millions / Billions unified ➡ (Pass)
Single Value Confirmation: All primary valuation and financial metrics successfully reconciled between official SEC 10-K/10-Q filings and third-party financial platform data, ensuring zero data conflicts ➡ (Pass)
Accounting anomalies/distortion signals (8/8): Exceptionally clean, transparent accounting with clear demarcation of all complex restructuring charges.
Cash flow warning signals (6/7): Superb cash conversion metrics, leaving the company heavily insulated from sudden liquidity shocks.
Dilution factors (2/5): Severe point deduction applied directly due to the imminent, unavoidable issuance of 280 million shares for the Kenvue acquisition, introducing massive equity dilution that alters the fundamental EPS growth math.
Step 4 Summary: Forensically, the core operations are pristine, conservatively managed, and generate vast amounts of real, liquid cash. However, the impending issuance of equity to fund the $48.7 billion Kenvue merger creates the most significant dilution event in the company’s 150-year history, requiring near-perfect integration execution to justify.
Q5-A1. Can You Trust Kimberly-Clark’s Management? (Guidance Track Record)
Guidance Track Record: CEO Mike Hsu has cultivated a solid, highly respected track record of under-promising and over-delivering to Wall Street. In recent quarters, Kimberly-Clark comfortably beat EPS consensus estimates (e.g., Q1 2026 actual $1.97 vs. $1.93 estimate) and has consistently navigated severe macroeconomic supply-chain shocks with far more agility than initial conservative guidances suggested.
Transparency: Management has been exceptionally transparent regarding the operational pain of severe input cost inflation and the difficult strategic decisions required to exit structurally low-margin businesses (such as intentionally exiting private label diapers, and fully divesting the PPE and IFP businesses to protect overall corporate margins).
Q5-A2. What Are Kimberly-Clark Insiders Doing?
Insider Trading Status: Institutional and insider SEC filings indicate that executives have been heavy net sellers over the trailing 12 months. Key officers such as Andrew Drexler (Controller) and Zackery Hicks (departing Chief Digital Officer) executed multi-million dollar sales in 2025 and 2026. Additionally, Katy Chen (President, International Personal Care) executed a string of sales throughout April and May 2026. While Todd Maclin (Director) made a notable $1.04 million open-market purchase in February 2026, the overwhelming volume of transactions consists of officer sales ahead of the Kenvue merger closure.
Evaluating Signals: The heavy selling pressure from insiders, while partially tied to routine compensation vesting and tax obligations, signals a distinct lack of psychological urgency to hold equity ahead of the massive integration risks of the Kenvue deal. The stark lack of cluster buying among the C-suite is a cautious signal that management acknowledges the difficulty of the impending turnaround.
Q5-A3. Is Kimberly-Clark’s Management Aligned With Shareholders?
Voting Rights and Governance: The company operates with a clean, standard “one share, one vote” structure without any complex dual-class shares or golden shares, ensuring fully democratic corporate governance. Shareholders recently voted to approve executive pay packages but notably rejected a push for an independent board chair, indicating general satisfaction with the current leadership structure.
Performance and Compensation Indicators (KPIs): Executive compensation is heavily weighted toward performance-based Annual Incentive Plans and long-term equity incentives. These metrics are tied directly to Adjusted ROIC, organic sales growth, and total shareholder return (TSR) relative to a basket of FMCG peers, ensuring executives are paid only when long-term value is sustainably created.
Management Trust (4/5): Highly transparent communication and a reliable track record of hitting operational margin targets despite inflationary headwinds.
Insider Trends (2/5): Significant point deduction due to the heavy, multi-million-dollar net selling by key operational officers over the past 12 months without corresponding cluster buying.
Governance & Compensation System (4/5): Clean single-class voting and tightly ROIC-linked compensation properly align management with long-term value creation.
Step 5 Summary: While the compensation structure and operational execution under CEO Mike Hsu are highly commendable and fundamentally sound, the heavy volume of insider selling ahead of the Kenvue acquisition closure warrants strict monitoring by investors to ensure management remains fully committed to the integration.
⛵ Step 6: Kimberly-Clark Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Kimberly-Clark Guidance
Guidance gap and direction analysis: Management’s full-year 2026 guidance projects mid-to-high single-digit growth in adjusted operating profit and impressive double-digit EPS growth on a constant currency basis. Analysts, however, remain cautiously optimistic, maintaining a broader consensus “Hold” rating with an average price target tightly grouped around $115 to $129. The consensus firmly aligns with company guidance on the core business, viewing the turnaround as intact, but heavily discounts the stock to price in the massive execution risk of the upcoming merger.
Tracking recent sentiment changes: Sentiment has oscillated violently. Following the Q1 2026 earnings beat, firms like Piper Sandler aggressively upgraded the stock to Buy ($121 target), citing highly manageable cost headwinds and expanded merchandising efforts. However, other firms remain strictly neutral, citing concerns over long-term pricing elasticity and the sheer mechanical difficulty of the Kenvue integration.
Q6-A2. What Is Kimberly-Clark’s Short Interest?
Institutional Trends: Institutional ownership is exceptionally high (approximately 93%), which is entirely typical for a mega-cap dividend staple. Notably, Capital Research Global Investors added heavily (+28.3 million shares) recently, indicating that deep-pocketed, long-term fundamental support remains robust.
Short Selling Indicators: The short interest sits at a highly elevated 12.78% to 13.42% of the float, with Days-to-Cover stretching to 9.7 days. This is an unusually extreme short position for a defensive, slow-moving consumer staple. This massive short interest is almost entirely driven by “Merger Arbitrage” hedge funds structurally shorting Kimberly-Clark stock to hedge their long positions in Kenvue (due to the fixed exchange ratio of 0.14625 KMB shares per KVUE share).
Consensus vs Guidance (2/3): Analyst targets are tightly grouped around the current trading price, indicating fair expectations, but notably lack aggressive upward momentum or conviction.
Supply/Short Interest (1/2): The ≈13% short interest creates a heavy, artificial mechanical overhang on the stock price until the Kenvue deal finally closes, thoroughly suppressing natural supply-and-demand discovery.
Step 6 Summary: Market sentiment is entirely paralyzed by the impending merger. While the core operations are demonstrably beating expectations, the stock’s price action is heavily dictated by arbitrageurs actively shorting the stock, creating a massive technical ceiling that will not break until the Kenvue deal resolves.
Q7-A1. What Could Move Kimberly-Clark Stock? (Top 3 Catalysts)
1 Official Closure and Synergistic Integration of the Kenvue Acquisition
Timing: H2 2026
Success Conditions: The $48.7 billion deal closes smoothly without further regulatory friction, and management immediately begins executing on the $1.9 billion in identified cost synergies, proving undeniable EPS accretion by year two.
Failure Risk: Integration chaos disrupts Kenvue’s retail distribution networks, forcing Kimberly-Clark to spend heavily to fix broken supply chains, effectively pushing synergy realization back by years and triggering a debt crisis.
2 Completion of the $1.7 Billion Suzano IFP Joint Venture
Timing: Mid-to-Late 2026
Success Conditions: The 51% divestiture closes seamlessly, instantly injecting $1.7 billion in hard cash into the balance sheet to directly offset the cash portion of the Kenvue purchase, while structurally lifting Kimberly-Clark’s total corporate profit margins by removing commoditized paper assets.
Failure Risk: Regulatory pushback in international markets delays the cash infusion, forcing Kimberly-Clark to issue costlier commercial paper to bridge the funding gap.
3 Deflation in Global Pulp and Resin Commodity Markets
Timing: Next 6-12 months
Success Conditions: If global oil and timber prices normalize downward, Kimberly-Clark’s recent aggressive retail price hikes will drop straight to the bottom line, exploding gross margins well past the targeted 38%.
Failure Risk: Severe geopolitical conflict (e.g., Middle East tensions) spikes crude oil to $100+ per barrel, violently wiping out the $3 billion productivity program’s gains and triggering a margin collapse.
Q7-A2. Kimberly-Clark’s Earnings Revision Trend
Tracking EPS estimate changes: Over the past 90 days, EPS revisions have been frustratingly mixed to slightly positive. Following the Q1 2026 earnings beat, 7 analysts revised estimates upward, while an equal 7 revised downward, reflecting the profound uncertainty in modeling the combined company.
Earnings expectations and momentum assessment: The market is fundamentally stalled in a holding pattern. Analysts actively refuse to aggressively revise 2027 or 2028 numbers upward until the combined, pro-forma financials of the massive KMB-KVUE entity are formally published post-close, creating a vacuum of forward-looking momentum.
Catalyst (6/7): The pending M&A deals provide massive, binary catalysts that will fundamentally re-rate the company’s valuation multiple across the entire sector if executed successfully.
EPS Trend (2/3): Revisions are utterly stagnant due to the profound mechanical complexities of modeling the upcoming merger, offering no near-term breakout signal.
Step 7 Summary: Kimberly-Clark is no longer a sleepy tissue company; it is the most significant event-driven powerhouse in the staples sector over the next 12 months. The closure of the Kenvue and Suzano deals will completely and irrevocably rewrite the company’s financial DNA.
⚖️ Step 8: Is Kimberly-Clark Fairly Valued? Valuation Analysis
Scoring Rationale: The forward P/E of 14.89x is highly attractive for a stable staple. However, the trailing multiples and EV/EBITDA sit squarely in the middle of historical norms. The extreme P/B ratio (20.77x) is a pure mathematical distortion caused by decades of treasury stock buybacks eroding book equity and absolutely does not reflect actual operational overvaluation.
📌 (1) Axis Q8-A1 Score:0
Q8-A2. Kimberly-Clark vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: -20.6%
🧮 Calculation Formula: ((14.89 - 18.75) / 18.75) × 100 = -20.58% (Benchmark average of PG ≈21x, CHD ≈23x, CL ≈23x vs KMB 14.89x).
Scoring Rationale: Kimberly-Clark is trading at a roughly 20% discount to its high-quality consumer staple peers. It is currently penalized by the market for its historical lack of explosive growth and the heavy technical overhang of the Kenvue merger arbitrage.
📌 (2) Axis Q8-A2 Score:+2
Q8-A3. Is Kimberly-Clark Cheap or Expensive vs Its History?
Comparison Indicators: Trailing P/E
Scoring Rationale: The 10-year historical average P/E for KMB is 21.7x. The current TTM P/E of 21.25x places it at the 48th percentile of its historical 5-year and 10-year bands. It is trading almost exactly at its long-term average, neither stretched nor deeply discounted relative to its own past.
📌 (3) Axis Q8-A3 Score:0
Q8-A4. What Growth Is Priced Into Kimberly-Clark? (Reverse DCF)
Implied Growth Rate:3.1%
1 Methodology: Standard Reverse DCF derived from the current $112.41 stock price, assuming a 7.5% discount rate and utilizing the TTM Free Cash Flow of $2.77B.
2 Core assumptions: Terminal growth rate set at 2.0%, applying standard WACC.
Achievable Growth Rate:5.2%
Basis: Consensus analyst EPS long-term growth estimates and explicit management guidance of mid-to-high single-digit operating profit growth moving forward.
Scoring Rationale: The market expects virtually zero real volume growth beyond basic inflation (3.1%). Management’s ongoing turnaround and margin expansion easily support a >5% bottom-line growth rate, indicating the stock is undervalued and market expectations are highly achievable.
(3) Axis Q8-A3 (Historical Band Position): Fairly Valued
(4) Axis Q8-A4 (Justification for Growth): Undervalued
The results are split 2:2 between Fairly Valued and Undervalued. Because there is no definitive 3-axis majority agreement, the conservative directional mismatch penalty must be applied.
📌 (5) Axis Q8-A5 Score:-2
Q8-A6. Kimberly-Clark’s Asset & Stake Valuation
Scoring Rationale: While the company is strategically selling a 51% stake in the IFP segment to Suzano for $1.7 billion, this is a straightforward divestiture at standard market multiples and does not constitute a deeply hidden “Sum-of-the-Parts (SOTP) premium” relative to its massive $37 billion market cap.
📌 (6) Axis Q8-A6 Score:➖
Q8-A7. Final Valuation Adjustment
Scoring Rationale: A +1 premium is confidently assigned because the impending Kenvue acquisition structurally shifts the company’s TAM from highly mature, commoditized paper products into the higher-margin, secular-growth consumer healthcare sector. This profound paradigm shift warrants a slight multiple expansion that standard, backward-looking metrics inherently cannot capture.
Commentary: The core legacy business is currently trading at absolute fair value compared to its own history, but it trades at a highly noticeable discount to its high-flying consumer staple peers. The market’s structurally low growth expectations provide a solid margin of safety.
Step 8 Summary: Kimberly-Clark is mildly undervalued. The stock’s current price is heavily anchored by the mechanical short-selling of the merger arbitrageur community, presenting a reasonably priced entry point before the $2.1 billion in Kenvue synergies unlock a much higher valuation multiple.
💀 Step 9: What Are the Risks of Kimberly-Clark? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Kimberly-Clark?
1 Kenvue Integration Failure and Synergy Destruction:
Cause: The sheer, unprecedented size of absorbing a $48.7 billion entity with vastly different regulatory requirements (FDA-regulated consumer health vs. basic tissue) overwhelms existing management bandwidth.
Impact: Financial (Massive margin compression, catastrophic failure to realize the $1.9 billion in promised cost synergies, leading to rapid EPS destruction and debt covenant violations).
Mitigation/Monitoring Indicators: Closely monitor quarterly updates on the $2.5 billion in expected cash integration costs and the precise tracking of overlapping SG&A headcount reductions over the next 24 months.
2 Structural Input Cost Inflation (Pulp and Resin):
Cause: Severe geopolitical instability or global supply chain breakdowns cause sustained spikes in global timber/pulp and petroleum-based resin prices.
Impact: Financial (Gross margins collapse back below 30% as the company hits the absolute ceiling of consumer price elasticity, finding itself unable to hike retail prices further without devastating volume losses).
Mitigation/Monitoring Indicators: Track global NBSK (Northern Bleached Softwood Kraft) pulp indices and crude oil futures as leading indicators.
3 Severe Consumer Down-Trading to Private Label:
Cause: A prolonged, brutal global recession heavily squeezes the middle class, forcing them to abandon premium Huggies and Kleenex for generic, low-cost store brands.
Impact: Multiple/Financial (Volume-plus-mix turns violently negative, collapsing organic sales growth and triggering a massive P/E multiple contraction as the growth narrative dies).
Mitigation/Monitoring Indicators: Watch Kimberly-Clark’s quarterly “Volume” vs. “Price/Mix” breakdown to ensure unit volumes aren’t plunging at the expense of price hikes.
Q9-A2. How Sensitive Is Kimberly-Clark to the Economy?
1 Global Commodity Cycles (Raw Materials) (⬇): The company is highly sensitive to basic input costs. If global pulp and oil prices surge, gross margins are immediately attacked until retail prices can be adjusted upward 3 to 6 months later, creating a severe margin lag.
2 Foreign Exchange Rates (Strong USD) (⬇): With 37% of pre-merger revenue (and growing significantly post-merger) coming from international markets, a persistently strong US Dollar acts as a severe translational headwind to reported EPS, constantly eroding overseas growth.
Q9-A3. Kimberly-Clark Pre-Mortem: What Could Go Wrong?
1 The M&A “Bite Too Big to Chew” Collapse: After issuing 280 million shares to acquire Kenvue, Kimberly-Clark discovers deep supply-chain rot and cultural mismatch inside Kenvue’s operations. The promised $7 billion in combined EBITDA never materializes, debt downgrades trigger much higher interest costs, and the stock halves as investors flee the bloated entity.
Early Warning Signal: The company announces a formal delay in synergy realization targets during the very first post-merger joint earnings call.
2 The Private-Label Surrender: Retail giants like Walmart and Costco aggressively push their own brand diapers and tissues, refusing to accept Kimberly-Clark’s continuous price hikes and delisting secondary SKUs from their shelves to protect consumer traffic.
Early Warning Signal: Two consecutive quarters of >5% volume declines specifically in the North America segment.
3 Debt Downgrade Crisis: The massive debt taken on to fund the Kenvue cash consideration ($6.8B upfront cash) violates covenant thresholds during a sudden recession, forcing management to institute a freeze on the beloved 53-year dividend growth streak.
Early Warning Signal: Moody’s or S&P issues a negative outlook or formally downgrades the company’s credit rating out of the A-tier.
Q9-A4. Risk Adjustment Score Calculation
📊 Risk Adjustment Score:-6 pts
Reason for Calculation: The risks are profound and structural—absorbing a $48.7 billion company is a monumental task fraught with immense execution peril. Additionally, the ≈13% short interest and persistent macro-inflationary inputs present constant friction. However, these are fundamentally “controllable” management execution risks for a highly cash-generative staple that produces daily-use necessities, warranting a mid-tier deduction rather than a catastrophic persistence risk deduction.
Step 9 Summary: The primary risk for Kimberly-Clark is no longer just selling tissues and diapers; it is the flawless financial, cultural, and operational execution of one of the largest consumer health mergers in modern corporate history.
🎯 Step 10: Kimberly-Clark Final Verdict: Score & Rating
Commentary: Kimberly-Clark scores respectably due to its absolutely pristine cash generation, unbeatable brand moat, and highly attractive forward valuation. However, the overall score is firmly suppressed by the massive impending equity dilution, extreme insider selling trends, and the short-term technical overhang of the Kenvue merger arbitrage.
Q10-A2. Should You Buy Kimberly-Clark? (Recommendation)
Recommendation:Hold
Commentary: The stock is a definitive “Hold” for current income investors enjoying the highly safe 4.55% dividend. However, for new capital, the execution risk of integrating a $48.7 billion acquisition, combined with a 13% short interest artificially pinning the stock, suggests waiting for clear post-merger financial clarity before initiating a massive new position.
Q10-A3. Investment Thesis in One Line
Investment Thesis: Kimberly-Clark offers an elite 4.5% dividend and a massive TAM expansion through the Kenvue merger (Bull), but extreme equity dilution and the monumental execution risk of integrating a $48.7 billion target cap near-term upside (Bear).
Stock Price Trends Over the Past 12 Months:Sideways movement
November 03, 2025Announced $48.7 Billion Cash-and-Stock Acquisition of Kenvue
Description: The shocking, historic pivot to consumer health instantly altered the company’s valuation framework, causing initial volatility as arbitrageurs stepped in to short KMB to hedge long KVUE positions. ➡ Sideways Volatility
April 28, 2026Q1 2026 Earnings Surprise and Gross Margin Expansion
Description: Delivering a $1.97 EPS beat and a 6% gross productivity gain via the 2024 Transformation Initiative proved the legacy business is fundamentally thriving, keeping a strong floor under the stock. ➡ Stock Price Stabilization
July 08, 2026Macro Risk-Off Selloff Amid Geopolitical Tensions
Description: Global crude oil spikes triggered severe fears of returning input cost inflation (resin/transportation), prompting a broad selloff in consumer staples despite their traditional defensive reputation. ➡ Stock Price Decline
Q10-A5. Action Plan
Current Price:$112.41
Buy Zone:$105.00 ($100.00–$110.00)
Commentary: By comprehensively considering the company’s traditional intrinsic value (safety margin) and current market momentum, it calculates a Actionable Buy Zone that minimizes opportunity costs.
(1) Calculation of Fundamental Value: The heavy short interest acts as an artificial ceiling. Entering closer to $105 ensures a near-5% dividend yield, establishing a historically proven valuation floor where value investors step in aggressively to support the stock.
(2) Momentum Premium/Discount Application: No momentum premium is granted. The stock is trapped in a strict merger-arbitrage holding pattern. Buying at a discount to current levels respects the severe dilution risk of the incoming 280 million shares required to close the Kenvue deal.
(3) Conclusion: The appropriate buying price range is $100.00–$110.00. The midpoint of $105.00 represents a flawless entry point that fully prices in the integration risks of the Kenvue acquisition.
Target Price:$120.80
Expected Return:+7.5% (vs. current price)
📍 Select target stock price calculation criteria:
Forward P/E Multiple — The most reliable baseline for a mature, dividend-paying consumer staple undergoing a structural TAM expansion.
🧮 Target Price Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): $7.55 × 16.0x = $120.80
Basis for applying the multiple: A 16.0x multiple is highly conservative, representing a discount to the sector average (18x-20x) and its own 10-year historical average (21.7x). This strictly penalizes the stock for the 280 million share dilution overhang until Kenvue synergies are definitively proven.
Conditions and timing for reaching target price: Achievement relies entirely on the successful Q4 2026 (post-merger) earnings report proving that the $1.9 billion cost synergies are actively being realized without sacrificing Kenvue’s retail shelf space.
Stop Loss & Investment Thesis Invalidation Criteria:$85.00 ($80.00–$90.00)
Fundamental damage criteria: The thesis is irrevocably broken if gross margins compress back below 32% due to uncontrollable pulp/oil inflation, or if the Kenvue integration triggers a formal credit downgrade that halts the company’s 53-year dividend growth streak.
Action trigger upon catalyst achievement:
1 Kenvue acquisition successfully closes and year-one synergy targets are raised
Description: Confirms management’s M&A competence and removes the massive short-selling merger arbitrage overhang from the stock. 👉 Increased Holdings (Buy)
2 Global pulp and crude oil prices collapse
Description: Instantly unlocks massive gross margin expansion beyond 38% as previous retail price hikes drop straight to the bottom line without corresponding cost pressures. 👉 Increased Holdings (Buy)
Action triggers when risk realization:
1 Q2/Q3 2026 earnings show North American volumes dropping >4% due to private-label down-trading
Description: Proves the company has exhausted its pricing power and consumers are fundamentally rejecting premiumization efforts in a tight economy. 👉 Reduction in Holdings (Sell)
2 The Suzano IFP joint venture is blocked by international regulators
Description: Deprives Kimberly-Clark of the vital $1.7 billion in cash needed to fund the Kenvue deal, forcing emergency debt issuance at highly unfavorable rates. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait for clear post-merger clarity. Hold current positions to collect the highly reliable 4.5% dividend, but absolutely do not allocate new capital until the Kenvue integration proves accretive to EPS.
Neutral Investors: Accumulate slowly on macro-driven dips below $110, treating the stock as a high-yield bond proxy with a free call option on future consumer-health growth.
Aggressive Investors: Capitalize on the artificial short-interest suppression. Buy aggressively in the low $100s before the arbitrageurs are forced to unwind their short positions upon the deal’s formal closure, triggering a rapid re-rating.
🕵️♂️ Deep Dive Analysis
Q1: Is Kimberly-Clark’s $48.7 Billion Acquisition of Kenvue Its Biggest Weakness?
Analysis: Historically, Kimberly-Clark operates a highly efficient, asset-intensive manufacturing model dedicated to producing paper-based staples with predictable demand. The Kenvue acquisition is a massive, unprecedented deviation, requiring the integration of a $48.7 billion FDA-regulated consumer health giant with entirely different supply chain and regulatory mechanics. The structural weakness lies strictly in the capital structure shock: paying $6.8 billion in upfront cash and heavily diluting existing shareholders by issuing 280 million new shares. This fundamentally alters the risk profile, pivoting the company from a safe, predictable dividend aristocrat into a highly leveraged turnaround integration story. If the projected $1.9 billion in cost synergies fail to materialize due to severe cultural clashes, or if retail distribution encounters hiccups during the systems merger, the resulting debt burden will crush earnings growth for a decade.
Judgment:Neutral — While the execution risk is historically unprecedented for the firm, the strategic logic of escaping the low-growth, hyper-commoditized paper tissue market and acquiring high-margin, sticky consumer health brands (Tylenol, Neutrogena) is fundamentally sound and ensures long-term relevance.
Q2: Can Kimberly-Clark’s 14.8x Forward P/E Be Justified by the Upcoming Integration Expansion?
Analysis: A 14.8x forward P/E is exceptionally cheap for a consumer staple, especially compared to structurally similar peers like P&G (21x) and Colgate-Palmolive (23x). The market is currently heavily discounting Kimberly-Clark due to the imminent 280-million share dilution and the complex operational execution risk of the Kenvue merger. However, Kenvue’s underlying assets generate incredibly robust, high-margin cash flows in markets with high barriers to entry. If management successfully achieves the $2.1 billion run-rate synergies by year two as promised, the combined entity’s EPS will surge dramatically, making the 14.8x multiple look like a deep-value anomaly in hindsight.
Judgment:Undervalued — The broader market is currently paralyzed by merger arbitrage mechanics and short-term integration fears, fully ignoring the combined entity’s massive $32 billion revenue scale and resulting, unprecedented pricing power over retailers.
Q3: Why Does Kimberly-Clark Have a High 13% Short Interest Despite Being a Defensive Staple?
Analysis: A ≈13% short interest in a boring, high-yield, dividend-paying tissue manufacturer is highly anomalous and rarely seen in the sector. This is not a fundamental bet by the market that Kimberly-Clark is going bankrupt; rather, it is a purely mechanical byproduct of “Merger Arbitrage.” Hedge funds are aggressively buying Kenvue stock (which is being acquired for $3.50 cash + 0.14625 KMB shares) and simultaneously shorting Kimberly-Clark stock to lock in the arbitrage spread before the deal officially closes. This creates a massive, artificial, mechanical ceiling on KMB’s stock price, completely divorced from its core operational performance.
Judgment:Positive — This short interest is entirely technical, not fundamental. Once the merger formally closes in H2 2026, these arbitrage funds will be forced to unwind their short positions, eliminating a massive source of artificial selling pressure and potentially creating a mild short-covering tailwind that pushes the stock higher.
Q4: Will the 2024 Transformation Initiative Actually Deliver $3 Billion in Gross Savings?
Analysis: The highly publicized initiative focuses on three core pillars: value stream simplification, network optimization, and scalable automation. In Q1 2026, management already proved a 6% gross productivity savings run-rate, indicating the operational execution is real, verifiable, and entirely on track. The structural exit from the margin-dilutive private label diaper business in the US proves management is deeply willing to sacrifice top-line vanity for bottom-line sanity. However, a significant portion of the $3 billion is simply required to offset the brutal realities of input cost inflation (timber, pulp, energy), meaning not all of it will flow through to bottom-line EPS expansion.
Judgment:Neutral — The targeted savings are highly real and quantifiable, but they are largely acting as a necessary defensive shield against commodity inflation rather than serving as pure, offensive margin expansion.
Q5: How Will the $1.7 Billion Suzano IFP Joint Venture Impact the Balance Sheet?
Analysis: By strategically selling 51% of its International Family Care and Professional (IFP) segment to Suzano, Kimberly-Clark accomplishes two vital objectives: it offloads lower-margin, highly commoditized paper operations, and it instantly raises $1.7 billion in hard cash. This cash is explicitly earmarked to directly help fund the $6.8 billion cash portion of the Kenvue acquisition, significantly reducing the amount of high-interest commercial debt the company must issue to close the deal.
Judgment:Positive — It is a masterstroke of portfolio optimization. Exchanging low-margin tissue assets for high-margin consumer healthcare assets while simultaneously minimizing new debt issuance perfectly aligns with long-term ROIC expansion.